preserved ejection fraction

Latest news

Tag

Comprehensive Review of the EMPEROR-Preserved Trial: Efficacy and Safety of Empagliflozin in Heart Failure with Preserved Ejection Fraction

This review synthesizes the pivotal EMPEROR-Preserved Trial results, highlighting empagliflozin’s efficacy in reducing heart failure outcomes in patients with preserved ejection fraction.

Nov 28, 2025

Cardiology

No Routine Benefit from Beta‑Blockers After Myocardial Infarction with Preserved Ejection Fraction: Individual‑Patient Meta‑analysis of Five Randomized Trials

An individual‑patient meta‑analysis of five randomized trials (n=17,801) found that beta‑blocker therapy did not reduce death, recurrent MI, or heart failure in patients with recent myocardial infarction and LVEF ≥50% without other indicati

Nov 10, 2025

Cardiology

Reevaluating Beta-Blocker Therapy Post-Myocardial Infarction with Preserved Ejection Fraction: Insights from Recent Trials and Meta-Analyses

Recent evidence challenges the routine use of long-term beta-blockers after myocardial infarction in patients with preserved ejection fraction, highlighting comparable outcomes with or without therapy and raising safety and efficacy conside

Sep 2, 2025Sign in to read